Welcome to the UPF Digital Repository

CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase

Show simple item record

dc.contributor.author Hernández-Sánchez, María
dc.contributor.author Kotaskova, Jana
dc.contributor.author Rodríguez, Ana E.
dc.contributor.author Radova, Lenka
dc.contributor.author Tamborero Noguera, David
dc.contributor.author Abáigar, María
dc.contributor.author Plevova, Karla
dc.contributor.author Benito, Rocío
dc.contributor.author Tom, Nikola
dc.contributor.author Quijada-Álamo, Miguel
dc.contributor.author Bikos, Vasileos
dc.contributor.author Martín, Ana África
dc.contributor.author Pal, Karol
dc.contributor.author García de Coca, Alfonso
dc.contributor.author Doubek, Michael
dc.contributor.author López Bigas, Núria
dc.contributor.author Hernández-Rivas, Jesús María
dc.contributor.author Pospisilova, Sarka
dc.date.accessioned 2019-06-11T07:31:25Z
dc.date.available 2019-06-11T07:31:25Z
dc.date.issued 2019
dc.identifier.citation Hernández-Sánchez M, Kotaskova J, Rodríguez AE, Radova L, Tamborero D, Abáigar M. et al. CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. Leukemia. 2019 Feb;33(2):518-558. DOI: 10.1038/s41375-018-0255-1
dc.identifier.issn 0887-6924
dc.identifier.uri http://hdl.handle.net/10230/41729
dc.description.sponsorship The research leading to these results has mainly received funding from the European Union Seventh Framework Programme [FP7/2007–2013] under Grant Agreement no 306242-NGS-PTL. In addition, this work was supported by grants from the Spanish Fondo de Investigaciones Sanitarias PI15/01471, PI18/01500, Instituto de Salud Carlos III (ISCIII), European Regional Development Fund (ERDF) “Una manera de hacer Europa”, “Consejería de Educación, Junta de Castilla y León” (SA085U16), “Proyectos de Investigación del SACYL”, Spain: GRS 994/A/14, BIO/SA10/14, BIO/SA31/13, GRS 1172/A/15,“Fundación Memoria Don Samuel Solórzano Barruso”, by grants (RD12/0036/0069) from Red Temática de Investigación Cooperativa en Cáncer (RTICC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00233 and USAL "Programa XIII". M. Hernández-Sánchez is supported by FEHH-Janssen (“Sociedad Española de Hematología y Hemoterapia”). M Quijada-Álamo is supported by an “Ayuda Predoctoral de la Junta de Castilla y León” (JCYL-EDU/529/2017). We are grateful to I. Rodríguez, S. González, T.Prieto, M. Á. Ramos, A. Martín, A. Díaz, A. Simón, M.del Pozo, V. Gutiérrez and S. Pujante from Centro de Investigación del Cáncer, Salamanca, for their technical assistance. D. Tamborero is supported by project SAF2015–74072-JUN, which is funded by the Agencia Estatal de Investigación (AEI) and Fondo Europeo de Dearrollo Regional (FEDER). This work was supported by Seventh Framework Programme (NGS-PTL/2012–2015/no.306242) and Ministry of Education, Youth and Sports (2013–2015, no. 7E13008); by the Ministry of Education, Youth and Sports of the Czech Republic under the CEITEC 2020 project (LQ1601); by the Ministry of Health, Czech Republic - conceptual development of research organization (FNBr, 65269705); by the Specific University Research (nr. MUNI/A/0968/2017) provided by MEYS; and by the project CZ.02.1.01/0.0/0.0/16_013/0001634 National Center for Medical Genomic - modernization of infrastructure and research of genetic variation in the population, funded by OP RDE. We acknowledge the CF Genomics CEITEC MU supported by the NCMG research infrastructure (LM2015091 funded by MEYS CR) for their support with obtaining the scientific data presented in this paper. We acknowledge S. Takacova from CEITEC MU for her help with the sample selection and processing.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Nature Research
dc.rights This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
dc.subject.other Leucèmia
dc.title CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1038/s41375-018-0255-1
dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/306242
dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2015–74072-JUN
dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/306242
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking